Gem-Disubstituted Piperidine MC2R Antagonists for Selective Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions related to excessive melanocortin receptor 2 (MC2R) activity, such as Cushing's syndrome and adrenal hyperplasia, suffer from significant side effects due to non-selective modulation of other melanocortin receptors, necessitating the development of selective MC2R modulators.
Innovation Solution
Development of gem-disubstituted piperidine compounds that act as selective MC2R antagonists, modulating MC2R activity without affecting other melanocortin receptors, thereby reducing unwanted side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective melanocortin receptor modulators are used to treat conditions related to excessive MC2R activity, then MC2R activity is modulated, but other melanocortin receptors are also affected causing significant side effects
Solution Approach 1:
The patent applies local quality by designing a molecule with distinct functional regions: a gem-disubstituted piperidine core provides selective MC2R binding, while specific substituent groups (R1-R6) are positioned to interact with MC2R-specific residues. This localized functional differentiation enables selective modulation of MC2R without affecting other melanocortin receptors, thereby reducing side effects while maintaining therapeutic efficacy.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical structure parameters of the piperidine core - specifically the gem-disubstitution pattern at positions 2, 3, or 4, and the nature of substituents R1-R6. These structural parameter modifications tune the binding affinity and selectivity for MC2R, optimizing the balance between therapeutic effect and side effect profile.
2Object-affected harmful factors
If selective MC2R antagonists are developed to reduce side effects, then selectivity is improved, but the complexity of achieving specific binding without affecting other receptors increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional segments: the gem-disubstituted piperidine core acts as the pharmacophore for MC2R selectivity, while separate substituent groups (R1-R6) are assigned specific roles in binding interaction. This modular segmentation simplifies the design process by allowing independent optimization of each segment for selective MC2R binding, reducing the overall complexity of achieving selectivity.
Data Source
AI summary
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.